109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
宏基因组学下一代测序揭示念珠菌血症的预后微生物协同作用并指导精准治疗：一项回顾性队列研究
Authors Chen Y , Li M, Gan X, Wang Y , Tang X, Zhou Y, Niu T
Received 27 May 2025
Accepted for publication 7 October 2025
Published 10 October 2025 Volume 2025:18 Pages 5263—5275
DOI https://doi.org/10.2147/IDR.S543151
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Héctor Mora-Montes
Yuhui Chen,1,2 Meng Li,1,2 Xinai Gan,1,2 Yutong Wang,1,2 Xinzhu Tang,1,2 Yongzhao Zhou,3,4 Ting Niu1,5,6
1Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2West China School of Medicine, Sichuan University, Chengdu, People’s Republic of China; 3Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 4Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 5State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 6National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, People’s Republic of China
Correspondence: Ting Niu, Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37 GuoXueXiang Street, Chengdu, Sichuan Province, 610041, People’s Republic of China, Email niuting@wchscu.cn Yongzhao Zhou, Integrated Care Management Center, West China Hospital, Sichuan University, No. 37 GuoXueXiang Street, Chengdu, Sichuan Province, 610041, People’s Republic of China, Email yongzhaozhou001@wchscu.cn
Purpose: Candidemia remains a life-threatening infection, compounded by diagnostic delays and limited prognostic tools. While metagenomic next-generation sequencing (mNGS) offers rapid pathogen detection, its prognostic utility and therapeutic impact in candidemia remain unestablished.
Patients and Methods: This retrospective cohort study analyzed 97 candidemia patients with positive blood mNGS at West China Hospital (2020– 2024). Multivariable logistic regression and survival analyses identified mortality predictors, while therapeutic impacts were assessed through antifungal regimen modifications.
Results: The 28-day mortality was 44.3% (43/97). Blood mNGS outperformed cultures in species identification (5 vs 4 species) and co-infection detection. Bacterial co-detections (HR=2.00, 95% CI:1.15– 3.48; p< 0.05) doubled mortality risk. SOFA score was the strongest mortality predictor (adjusted OR=1.29 per point; p< 0.001). mNGS-guided antifungal initiation reduced mortality by 52.4% in treatment-naïve patients (22.6% vs 75.0%; p< 0.05), though regimen adjustments in pretreated cases showed no benefit (p> 0.05). Notably, Candida species exhibited equivalent virulence (log-rank p> 0.05), and mNGS read counts lacked prognostic value (p> 0.05).
Conclusion: mNGS transforms candidemia management by enabling early risk stratification (via SOFA scores and co-infection profiles) and precision therapy initiation. Its capacity to unmask high-risk bacterial synergists and guide time-sensitive interventions supports integration into diagnostic algorithms, particularly for culture-negative cases. Further validation of standardized mNGS protocols is warranted to maximize clinical impact.
Keywords: candidemia, metagenomic next-generation sequencing, mNGS, prognostic model, microbial synergism, precision therapy
1Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2West China School of Medicine, Sichuan University, Chengdu, People’s Republic of China; 3Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 4Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 5State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 6National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, People’s Republic of China
Correspondence: Ting Niu, Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, No. 37 GuoXueXiang Street, Chengdu, Sichuan Province, 610041, People’s Republic of China, Email niuting@wchscu.cn Yongzhao Zhou, Integrated Care Management Center, West China Hospital, Sichuan University, No. 37 GuoXueXiang Street, Chengdu, Sichuan Province, 610041, People’s Republic of China, Email yongzhaozhou001@wchscu.cn
Purpose: Candidemia remains a life-threatening infection, compounded by diagnostic delays and limited prognostic tools. While metagenomic next-generation sequencing (mNGS) offers rapid pathogen detection, its prognostic utility and therapeutic impact in candidemia remain unestablished.
Patients and Methods: This retrospective cohort study analyzed 97 candidemia patients with positive blood mNGS at West China Hospital (2020– 2024). Multivariable logistic regression and survival analyses identified mortality predictors, while therapeutic impacts were assessed through antifungal regimen modifications.
Results: The 28-day mortality was 44.3% (43/97). Blood mNGS outperformed cultures in species identification (5 vs 4 species) and co-infection detection. Bacterial co-detections (HR=2.00, 95% CI:1.15– 3.48; p< 0.05) doubled mortality risk. SOFA score was the strongest mortality predictor (adjusted OR=1.29 per point; p< 0.001). mNGS-guided antifungal initiation reduced mortality by 52.4% in treatment-naïve patients (22.6% vs 75.0%; p< 0.05), though regimen adjustments in pretreated cases showed no benefit (p> 0.05). Notably, Candida species exhibited equivalent virulence (log-rank p> 0.05), and mNGS read counts lacked prognostic value (p> 0.05).
Conclusion: mNGS transforms candidemia management by enabling early risk stratification (via SOFA scores and co-infection profiles) and precision therapy initiation. Its capacity to unmask high-risk bacterial synergists and guide time-sensitive interventions supports integration into diagnostic algorithms, particularly for culture-negative cases. Further validation of standardized mNGS protocols is warranted to maximize clinical impact.
Keywords: candidemia, metagenomic next-generation sequencing, mNGS, prognostic model, microbial synergism, precision therapy